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Abstract
Background: In many Asian countries, Klebsiella pneumoniae (KP) is the second pathogen responsible for
community-acquired pneumonia. Yet, very little is known about KP etiology in ALRI in Cambodia, a country that
has one of the weakest medical infrastructures in the region. We present here the first clinico-radiological
description of KP community-acquired ALRI in hospitalized Cambodian patients.
Methods: Through ALRI surveillance in two provincial hospitals, KP was isolated from sputum and blood cultures,
and identified by API20E gallery from patients ≥ 5 years-old with fever and respiratory symptoms onset ≤14 days.
Antibiotics susceptibility testing was provided systematically to clinicians when bacteria were isolated. We collected
patients’ clinical, radiological and microbiological data and their outcome 3 months after discharge. We also
compared KP-related with other bacteria-related ALRI to determine risk factors for KP infection.
Results: From April 2007 to December 2009, 2315 ALRI patients ≥ 5 years-old were enrolled including 587 whose
bacterial etiology could be assigned. Of these, 47 (8.0%) had KP infection; their median age was 55 years and
68.1% were females. Reported prior medication was high (42.5%). Patients’ chest radiographs showed pneumonia
(61.3% including 39% that were necrotizing), preexisting parenchyma lesions (29.5%) and pleural effusions alone
(4.5%) and normal parenchyma (4.5%). Five patients had severe conditions on admission and one patient died
during hospitalization. Of the 39 patients that were hospital discharged, 14 died including 12 within 1 month after
discharge. Only 13 patients (28%) received an appropriate antibiotherapy. Extended-spectrum beta-lactamases
(ESBL) - producing strains were found in 8 (17.0%) patients. Female gender (Odds ratio (OR) 2.1; p = 0.04) and
diabetes mellitus (OR 3.1; p = 0.03) were independent risk factors for KP-related ALRI.
Conclusions: KP ALRI in Cambodia has high fatality rate, are more frequently found in women, and should be
considered in diabetic patients. The extremely high frequency of ESBL-producing strains in the study is alarming in the
context of uncontrolled antibiotic consumption and in absence of microbiology capacity in most public-sector hospitals.
Keywords: Klebsiella pneumoniae, Community-acquired, Pneumonia, Extended-spectrum betalactamases, Diabetes
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Background
Klebsiella pneumoniae (KP) is a Gram negative bacillus
often involved in severe community-acquired and noso-
comial infections [1]. It has been proven to be an inde-
pendent risk factor for mortality in severe community-
acquired pneumonia (CAP) [2]. Its distribution as a
CAP pathogen is uneven across the world with a highest
incidence in developing countries and in Asia [3-5]. To
explain these geographical patterns, hypotheses include
differences in virulence of strains, host defences and the
importance of antibiotic consumption in self-medication
[6,7]. KP is naturally resistant aminopenicillins (i.e.
ampicillin or amoxicillin), an antibiotic that is com-
monly used as the first line antibiotherapy in CAP in
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since a recent multicenter prospective study conducted
in several Asian countries (not including Cambodia)
showed KP accounted for 15.4% of the pathogens
responsible for hospitalized CAP, just after Streptococcus
pneumoniae [8]. Last, emerging resistances among
Gram-negative bacilli such as extended-spectrum beta-
lactamases (ESBL) are increasingly recognized as a
major public health issue in both developed and devel-
oping countries [9,10].
In Cambodia - one of the poorest countries in the
region with ill-equipped health care facilities - microbial
identification is a challenge and antimicrobial resistance
detection is poorly documented. This study aimed at
better characterizing hospitalized patients with KP-
related acute lower respiratory infections (ALRI) in
Cambodia collecting clinical, radiological and microbio-
logical data.
Methods
Beginning in April 2007, we conducted surveillance of
ALRI in two Cambodian provincial hospitals. Eligible
patients (≥5 years-old) included those with ALRI defined
by onset symptoms ≤14 days, a fever of ≥ 38°C (axillary
temperature using digital thermometers) or a history of
fever within the previous 3 days, recent cough, plus at
least one respiratory symptom (i.e. dyspnea, chest pain
or crackles on lung auscultation). Patients with known
tuberculosis (TB) or known acquired immunodeficiency
were not included. For each participant, hospital physi-
cians filled out a standardized case report form includ-
ing information on patient’s medical history, clinical
features, treatment, laboratory and radiological findings
and status at discharge. Medical records and chest X-
rays were retrospectively reviewed by an expert pulmo-
nologist. A home visit was conducted at least 3 months
following hospital discharge to determine the outcome
of the KP-infected patients. The surveillance project was
approved by the National Ethical Committee. All
patients and parents of <18 year-old patients who parti-
cipated provided written informed consent.
Specimens’ collection and microbiology
Blood, non-induced sputum, and nasopharyngeal swabs
were collected in each participant once within 48 h after
hospital presentation for direct examination, cultures
and molecular diagnostic. Sputum and blood (10 mL in
Hemoline Diphasic Performance bottle (bioMérieux,
Marcy l’Etoile, France) for adult and Isolator 1.5 (Oxoid,
Basingstoke, England) (1.5 mL for children) were sent to
Institut Pasteur in Cambodia to perform Gram stain
and culture. Only good-quality sputum specimens were
submitted for bacterial cultures using Murray-Washing-
ton’s score (>25 polynuclear leukocytes and <25
squamous epithelial cells per low-power field) [11]. Spu-
tum specimens were inoculated on colistin-nalidixic acid
agar, cystine-lactose-electrolyte-deficient agar, chocolate
polyvitex agar with bacitracin and Ashdown agar. Bac-
terial isolates were identified by API gallery (BioMér-
ieux). Antibiotic susceptibility testing was performed by
disk-diffusion method on Mueller-Hinton agar plates
(Bio-Rad, Marnes-la-Coquette, France). ESBL production
was detected by using the double-disk synergy test (cla-
vulanic acid and cefotaxime, ceftazidime, cefepime and
aztreonam) performed on Mueller-Hinton media.
Complete microbiology results were returned to the
patient’s hospital clinicians as soon as they were avail-
able. Microscopy for acid fast bacilli detection was sys-
tematically performed at the hospital laboratory, and TB
culture where indicated in the guidelines of the national
TB program.
Definitions
KP-infected cases were defined by identification of KP in
either blood or sputum culture. A significant growth of
KP was defined as greater than 10
7 organisms per mL of
original sputum.
A severe case was defined by the presence of at least
two of the following criteria: systolic blood pressure
(BP) < 90 mmHg, cardiac frequency ≥120 bpm, respira-
tory rate ≥30/mn, oxygen saturation <90%, temperature
<35°C or ≥40°C. Severity definition was adapted to the
Cambodian setting from PSI and CRB65 scores [12].
Since no patient was taking anti-diabetic drug and fast-
ing plasma glucose was not always available, we defined
as diabetic every patient with glycemia >7.8 μmol/L or
with a medical history of diabetes mellitus [13].
Renal impairment was defined as a serum creatinine
>150 μmol/L and liver disease by a history of chronic liver
involvement. Cardiovascular disease was defined by a his-
tory of high blood pressure or cardiomegaly on chest X-
ray or known cardiopathy. Having TB was defined by a
positive AFB smear, as 97% of them were linked to a posi-
tive culture for Mycobacterium tuberculosis in Cambodian
hospitalized patients (unpublished data). A necrotizing
pneumonia was defined by the presence of either cavity or
abscess, unique or multiple. We created a separate preex-
isting lung lesions diagnostic group as these lesions may
alter or disguise the appearance of a pneumonic infiltrate.
The ALRI with normal radiography group consisted of
patients presenting with symptoms of acute bronchitis and
normal lung parenchyma radiographs [14,15]. Expert pul-
monologists retrospectively interpreted radiographs una-
ware of the microbiology diagnosis.
Statistical analyses
We analyzed variables associated with mortality among
patients with KP infection. In addition, we compared
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philus influenzae and Streptococcus pneumoniae (H&S),
the two main pyogenic bacteria identified in patients in
both hospitals to determine clinical/radiological charac-
teristics associated with KP infection. Variables that
were tested by univariate analysis included age, gender,
comorbidities, prior treatment to admission, hemoptysis,
chest pain, severity on admission, pneumonia, necrotiz-
ing pneumonia, uncomplicated pneumonia, pleurisy,
preexisting pulmonary lesions and TB co-infection. For
mortality-associated risk factors, the variable “receiving
an appropriate antibiotherapy” was added into the ana-
lyses. Variables for which a p-value in stratified analysis
was ≤0.2, were further analyzed using a stepwise forward
logistic regression model. Statistical analyses were per-
formed using STATA version 9.2 (Statacorp, College
Station, TX, USA). Odds ratio (OR) and 95% confidence
interval (CI) were calculated for all variables significantly
associated with KP infection or mortality.
Continuous variables were presented with their med-
ian and inter quartile range (IQR) or mean and mini-
mum/maximum ranges. Variables were compared across
groups using Wilcoxon-Mann-Whitney test for continu-
ous variables, and the Chi-square or Fisher’s exact test
for categorical variables. For all analyses, statistical sig-
nificance was defined at P < 0.05.
Results
Patients characteristics
From April 2007 to December 2009, 2315 ALRI patients
≥5 years-old were enrolled including 587 whose bacter-
ial etiology could be assigned. Of these, 47 (8.0%) had
KP infection. The median age of KP-infected cases was
55 years (range 25-79). Women were predominant (n =
32; 68.1%); of which 72% aged >45 years. Main comor-
bidities or known risk factors included chronic lung dis-
ease (n = 13), smoker (n = 10), cardiovascular disease (n
= 7), diabetes mellitus (n = 7), alcoholism (n = 6), renal
impairment (n = 3), liver disease (n = 1). Treatment
prior to hospitalization was reported in 20 patients
(42.5%), of which 5 reported the use of antibiotics.
Reports of cigarette smoking and excessive alcohol
drinking (≥1 glass of rice wine or few beer cans per day)
were significantly more frequent in males than females
(6/14 versus 0/29; p < 0.001). Distribution of other
comorbidities did not significantly differ between gen-
ders or age groups.
Clinical, biological and radiological features on admission
Onset of symptoms occurred on average within 9 days
before presentation (range 1-14 days).
On admission, patients presented with fever >38°C (n
=3 0 ;6 3 . 8 % ) ,c h e s tp a i n( n=2 8 ;5 9 . 6 % ) ,c o u g h( n=2 6 ;
55.3%), and/or hemoptysis (n = 11; 23.4%). Five (10.6%)
patients had at least 2 severity criteria of which none
had hemoptysis. Interpretation of the 44 chest radio-
graphs that were available yielded 27 (61.3%) pneumonia
(i.e. 2 associated with pleural effusion and 14 with cavi-
tations), 13 (29.5%) preexisting pulmonary lesions
(bronchiectasis and/or infectious sequelae with cavita-
tion, fibrosis, retraction, pleural thickening), 2 (4.5%)
pleural effusion and 2 with normal parenchyma. For the
latter group, both radiographies showed a thoracic
hyperinflation, suggestive of a chronic obstructive pul-
monary disease. Of the 10 patients who had hemoptysis
and available chest X-rays, 4 had preexisting lung
lesions and 6 had pneumonia including 5 with cavita-
tions. Of note, AFB were found on direct sputum exam-
ination in only 2 cases. Among the 5 severe cases, 3 had
pneumonia without cavities, 1 had pleural effusion and
1 had preexisting lung lesions. Females had significantly
more radiological evidence of pneumonia than males
(55.6% vs. 44.4% respectively; p = 0.02).
Microbiological data
KP grew from 46 (97.8%) sputum cultures and 1 blood cul-
ture. No patients had both positive sputum and blood cul-
tures. In 5 cases, other bacteria (S. pneumoniae,n=3 ;H
influenza,n=1 ,Staphylococcus aureus,n=1 )g r e w
together with KP. AFB was also identified in six (12.8%)
patients. Viruses (respiratory syncytial virus, n = 7; influ-
e n z aBv i r u s ,n=2 ;h u m a nr h i n o v i r u s ,n=2 ,i n c l u d i n go n e
rhinovirus and respiratory syncytial virus co-infection) was
found in 21.3% (n = 10/47) of the patients. Bacterial or viral
coinfections were not associated with severity. Resistance to
cotrimoxazole was present in 32.3% (n = 10) of the strains
and resistance to ciprofloxacin was detected in only one
strain. ESBL production was detected in 17.0% (n = 8) of
the strains cultured from sputum specimens. All patients
infected with ESBL-producing strains were women. One
patient had a medical history of diabetes mellitus, one had
a cardiopathy and another one had pulmonary TB sequelae.
Comorbidities distribution was not significantly different in
patients with and without ESBL-producing KP. ESBL pro-
duction was frequently associated with gentamicin resis-
tance (50%; n = 4/8) and in most cases with susceptibility
to ciprofloxacin (n = 7/8) and fosfomycine (n = 8). Suscept-
ibility testing of the 39 non-ESBL producing KP strains
were as follows: amoxicillin/clavulanic acid, 94.7% (37/39),
cefotaxime, 97.4% (38/39), cefepime, 96.7% (29/30), ceftazi-
dime, 97.4% (38/39), ticarcilline, 2.5% (1/39), imipenem
97.4% (38/39), nalidixic acid, 83.3% (25/30), ciprofloxacine,
92.3 (36/39), gentamicin, 89.7% (35/39), amikacin, 97.4%
(38/39), cotrimoxazole, 61.3% (19/31).
Comparison between KP and H&S infected patients
As 4 patients were co-infected with KP and H&S,w e
compared the 43 KP to the 160 H&S infected patients
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There was a significantly higher proportion of females
(67.4 vs. 50.0%; p = 0.04) in the KP group compared
with the H&S group. Of all reported co-morbidities,
only diabetes mellitus was more frequently associated
with KP-infected patients than H&S-infected patients
(16.3% vs 6.0%; p = 0.02). Biological results did not dif-
fer between KP and H&S infected patients (Table 1).
There was no difference between radiological findings
in both groups as shown in Table 2. Based on multivari-
ate analysis, female gender (OR = 2.1; 95%CI [1.0-4.5]; p
= 0.04) and diabetes mellitus (OR = 3.1; 95%CI [1.1-9.1];
p = 0.03) were independent risk factors for KP-related
ALRI.
Treatment and outcome
In the KP group, 47 received antibiotics during their
hospital stay, two patients were transferred to another
ward or hospital and one left the hospital before being
treated, probably because the family could not afford
the hospitalization costs. Appropriate first line antimi-
crobial therapy (ceftriaxone, amoxicillin/clavulanic acid,
cotrimoxazole or ciprofloxacin) was prescribed to only
four patients (9.0%). In the remaining 40 patients,
penicillin A was given (n = 39/40; 97.5%), in combina-
tion with gentamicin in 13 patients (33%) while one
patient only received macrolides. This antimicrobial
therapy was appropriately modified in nine (22.5%).
Only 2 of 8 patients with ESBL-producing KP received
an appropriate treatment and were considered as cured.
For these patients, the treatment was adapted following
antibiotic susceptibility. The overall length of stay at the
hospital was on average 10.7 days (range 1-35) and
longer for patients appropriately treated compared with
that of patients without appropriate treatment (13.3
(range 3-21) vs 9.7 days (range 1-35); p =0 . 0 1 ) .O nd i s -
charge, 59.6% (n = 28/47) of the patients were consid-
ered as cured by clinicians, one patient died during
hospitalization and the outcome was unknown for 18
(38.3%) patients (14 were transferred to another ward or
hospital and 4 escaped). Thirty-nine patients could be
located for home visit. Of these, 14 (35.9%) died includ-
ing 12 and two within 1 month and 6 weeks after dis-
charge, respectively; none received an appropriate
treatment. Twenty five (64.1%) were considered having
recovered of which 13 received an appropriate treat-
ment. Among the eight patients infected by ESBL-pro-
ducing strains, three died within 1 month, two were not
Table 1 Characteristics on admission of K. pneumoniae infected patients compared to patients with H. influenzae/S
pneumoniae ALRI aged ≥5 years in univariate analysis
Patients with K. pneumoniae
ALRI
(n = 43)
Patients with H. influenzae and S. pneumoniae
ALRI
(n = 160)
P-
value
Age, median years (Inter Quartile Range
[IQR])
55 (45-72) 57 (42-65) 0.8
Male gender (%) 14 (32.6) 80 (50.0) 0.04
Co-morbidities (%)
Smoking history 10 (23.3) 50 (31.2) 0.3
Cardiovascular disease 6 (13.9) 17 (10.6) 0.5
Diabetes mellitus 7 (16.3) 10 (6.2) 0.03
Alcoholism 6 (13.9) 35 (21.9) 0.2
Renal impairment 3 (7.0) 10 (6.2) 0.8
Liver disease 1 (2.3) 1 (0.6) 0.3
Prior treatment 19 (44.2) 92 (57.5) 0.08
Prior antibiotic 5 (11.6) 7 (4.4) 0.08
Clinical data
Chest pain 24 (55.8) 106 (66.2) 0.1
Hemoptysis 10 (23.2) 23 (14.4) 0.1
Severity criteria 5 (11.6) 8 (5.0) 0.1
Laboratory results
Leucocytes, median 10
9/L (IQR) 8.5 (6.7 - 10.8) 8.3 (6.2 - 10.6) 0.6
AST*, median U/L (IQR) 29 (25-42) 27.5 (21-38) 0.1
ALT*, median U/L (IQR) 30 (21-32) 26 (20-34) 0.4
Blood creatinine μmol/L (IQR) 88.4 (77.8 - 108.7) 88.4 (76.0 - 99.0) 0.6
NOTE. Liver enzymes: AST (Aspartate transaminase) and ALT (Alanine transaminase)
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an appropriate antimicrobial therapy. As a result, the
overall case fatality rate was 37.5% (15/40). Receiving an
incorrect antimicrobial therapy was not a risk factor for
mortality, although comorbidities, clinical and radiologi-
cal features were not significantly different between sur-
vivors and non survivors (p = 0.12). Of the 12 patients
who received at discharge incorrect treatment, none
were considered severe. At the follow-up visit, 43.3%
(13/30) of the patients who did not receive an appropri-
ate treatment were alive.
Discussion
This is the first clinico-radiological description of a sub-
stantial number of community-acquired KP ALRI in
hospitalized patients in Cambodia. Our findings con-
firmed that KP-related respiratory infections carried
poor prognosis with high fatality rates, longer hospital
stays and was associated with older ages and co-morbid-
ities. More importantly, KP pneumonia was frequently
unsuspected and the initial antimicrobial treatment was
often inappropriate. Yet, we found from this surveillance
project that KP was the second pyogenic bacterium
found among severe CAP in patients aged 5 years and
older, and the 4th in infections on preexisting pulmon-
ary lesions in Cambodia (Institut Pasteur’su n p u b l i s h e d
data). Moreover, the high frequency of ESBL-producing
strains in KP infection was particularly worrisome. The
ESBL resistance among community-acquired infections
varied from 0% (Taiwan, South Korea, Malaysia) to
36.4% (India), but the incidence is not well studied in
Cambodia or neighboring countries [16]. In a multicen-
ter study in Asian countries determining CAP etiologies,
antibiotic susceptibility testing was done for 36 strains
of KP [8]. All but one were susceptible to ceftriaxone.
Another international multicenter study conducted in
Taiwan, Argentina, South Africa, Europe, United States,
and Australia, showed an incidence of community-
acquired ESBL-producing KP was of 3.5% (n = 7/202),
all patients but one had a history of prior hospitalization
[6]. In contrast, none of our patients with ESBL-produ-
cing strain reported previous hospitalization within the
month prior to admission. In our cohort, 42.5% of the
patients reported having taken treatment prior to hospi-
talization although the proportion of actual intake of
antimicrobial drugs was not known. In the Cambodian
context, it is believed however that this proportion may
be high as patients have access to antibiotics and corti-
costeroids without medical prescription, through formal,
informal and unregulated private health sectors [17].
Overuse and misuse (e.g. incorrect dosage) of antibiotics
is a known risk factor for developing ESBL-producing
strains [18]. Interestingly, a Cambodian study recently
conducted in the capital city showed that up to 37% of
the E. coli strains isolated from community acquired
urinary tract infections carried ESBLs, of which all were
CTX-M type [19].
Female gender and diabetes mellitus are independent
risks factors associated with KP ALRI in Cambodia. Sur-
prisingly, women accounted for more than two thirds
(68.1%) of all cases. Published data report that commu-
nity-acquired KP are associated with male gender,
women accounting for 20% to 42% of the studied popu-
lations [1,6,20,21]. There was a trend to a higher anti-
biotic intake prior to hospitalization in women, whereas
no data informed about health seeking behavior among
women in Cambodia to confirm this tendency. Whereas
age was not statistically different between men and
women, 72% of women in our study were postmenopau-
sal. Postmenopausal women are at risk to develop cer-
tain infections such as atypical mycobacterial infections
[22]. In animals’ models, the role of sex hormones in
susceptibility to lung infections has been well demon-
strated [23]. Higher frequency of diabetes mellitus in KP
CAP patients was consistent with commonly reported
association between diabetes condition and community-
acquired KP bacteremia or community-acquired pleural
effusion [24,25].
Table 2 Radiological data on admission for 40 K. pneumoniae compared to 146 H. influenzae & S.pneumoniae infected
patients aged ≥5 years in univariate analysis
Patients with K. pneumoniae ALRI
N = 40 (%)
Patients with H. influenzae and S. pneumoniae ALRI
N = 146 (%)
P-value
Pneumonia 25 (62.5) 68 (46.6) 0.05
Consolidation 16 (40.0) 51 (34.9) 0.3
Consolidation with cavitation 9 (22.5) 17 (11.6) 0.07
Consolidation with pleural effusion 2 (5.0) 6 (4.1) 0.5
Pleural effusion alone 1 (2.5) 0 (0.0) 0.2
Preexisting lung diseases 12 (30.0) 62 (42.5) 0.1
Normal parenchyma
a 2 (5.0) 16 (10.9) 0.2
NOTE. Data are no. (%) of patients
aA chronic pulmonary disease cannot be excluded as chest computed tomography scan and pulmonary function tests were not available
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mic country. Hemoptysis is known to be associated with
KP necrotizing pneumonia but is rarely described in the
literature [26]. In our series, ~20% of the patients
infected by KP had hemoptysis on admission. We failed
to demonstrate an association between KP and hemop-
tysis as the frequency of TB and bronchiectasis–known
as confounding factors–was high in our cohort KP
accounted for 4.5% of documented pleural effusion. This
number is lower than proportions found (12 to 23.6%)
in other Asian countries [18,27,28]. As bacteriological
analysis of pleural fluids was not available in our study,
the proportion of KP pleural effusion might be
underestimated.
Our finding also pointed to the fact many patients did
not receive an appropriate antimicrobial treatment
although the causal agent bundled with antibiotics sus-
ceptibility testing results was made available as soon as
possible. Several reasons may explain this: (i) antibiotics
susceptibility results were sent to the hospital while
patients were already discharged (families usually request
discharge when no hope of cure is expected), (ii) treat-
ments may have been too expensive for some patients
and their relatives, (iii) the prescription of penicillin A as
a first line antibiotic in ALRI was the rule in these 2 hos-
pitals but is known to be inefficient against KP.A n o t h e r
point is, the high prevalence of pulmonary sequelae, par-
ticularly TB sequelae in a highly endemic country, may
be the cause of KP bronchiectasis colonization. In 50
Thaï patients diagnosed with bronchiectasis, KP was the
second isolated bacterium (14%). Unfortunately, the
authors did not report as whether this pathogen was
found during an acute exacerbation or not [29].
Some limitations have to be underlined. The project
was implemented for surveillance of ALRI related etiolo-
gies in settings where microbiology capacity was inexis-
tent, although we were able to capture about all the
patients who were admitted with acute respiratory
symptoms, the frequency and the quality of specimens’
collection for diagnosis was insufficient. Only ~50% of
all included patients had available sputum (unpublished
data). Capacity for more refined diagnosis was also lim-
ited by the absence of computed tomographic scan or
capacity for aspiration by bronchial fibroscopy. Addi-
tionally, no colony forming unit/mL threshold was vali-
dated in patients with preexisting pulmonary lesions. In
the context of surveillance, we did not request systema-
tic verification of bacterial eradication at the end of the
treatment, which made it difficult to confirm the causal
implication of KP in the respiratory infection.
Conclusions
Nevertheless, despite these limitations, our first docu-
mented series of KP-infected cases in Cambodia have
shown particularly relevant information for Cambo-
dian clinicians. As a result, we recommend a change
of the current national approach in managing ALRI at
the hospital level in the country. Antibiotics which
include KP in their spectrum (i.e. amoxicillin/clavula-
nic acid, ceftriaxone) should be used when the first
line antimicrobial therapy (mainly penicillin A in
national Cambodian guidelines) fails or in case of
necrotizing pneumonia. In any case, it is crucial for
Cambodia to be able to acquire adequate microbiolo-
gical capacity (i.e. culture) in public hospitals. Finally,
the emergence or the rise of ESBL-producing strains
causing community-acquired infections in Cambodia
should draw the attention of the Cambodian health
authorities as well as the international public health
community.
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